Deenan Pillay

Deenan Pillay

Professor Deenan Pillay is Africa Health Research Institute’s Director and a member of AHRI Faculty. He is an academic clinical virologist with a research and clinical interest in HIV transmission, antiviral therapy and drug resistance. Deenan is also a Professor in Virology in the University College London (UCL) Division of Infection & Immunity and is Deputy Director for Clinical Research at i-sense.

Deenan’s research work at UCL and AHRI focusses on HIV virus evolution; in particular how HIV escapes drug selective pressure. His research spans wet (genomic, phenotypic) and dry (bioinformatics) laboratory approaches, as well as linking in vitro data to national and international population estimates. Prior to his posting as Director of Africa Health Research Institute, he served as Director of the Africa Centre for Population Health. Deenan previously led the virology work in the pivotal UK MRC-funded DART trial of antiretroviral therapy to estimate the impact of drug resistance on the efficacy of treatment rollout in endemic areas, feeding into WHO guidelines. He is PI on the BMGF Pangea HIV consortium, which maps HIV transmission dynamics through full length viral sequencing. He was also PI on the ANRS Treatment as Prevention Trial.

Click here for a full list of publications.

Selected Recent Publications

Haber, N., Tanser, F., Bor, J., Naidu, K., Mutevedzi, T., Herbst, K., Porter, K., Pillay, D., & Bärnighausen, T. (2017). From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa. The Lancet HIV, 4(5), e223-e230. doi: https://doi.org/10.1016/S2352-3018(16)30224-7.

Gregson, J., Kaleebu, P., Marconi, V. C., van Vuuren, C., Ndembi, N., Hamers, R. L., Kanki, P., Hoffmann, C. J., Lockman, S., & Pillay, D. (2017). Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. The Lancet infectious diseases, 17(3), 296-304.

Boyer, S., Iwuji, C., Gosset, A., Protopopescu, C., Okesola, N., Plazy, M., Spire, B., Orne-Gliemann, J., McGrath, N., Pillay, D., Dabis, F., & Larmarange, J. (2016). Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa. AIDS Care, 28 Suppl 3, 39-51. doi: 10.1080/09540121.2016.1164808.

Maheu-Giroux, M., Tanser, F., Boily, M.-C., Pillay, D., Joseph, S. A., & Bärnighausen, T. (2017). Determinants of time from HIV infection to linkage-to-care in rural KwaZulu-Natal, South Africa. Aids, 31(7), 1017-1024.

Oldenburg, C. E., Barnighausen, T., Tanser, F., Iwuji, C. C., De Gruttola, V., Seage, G. R., 3rd, Mimiaga, M. J., Mayer, K. H., Pillay, D., & Harling, G. (2016). Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa. Clin Infect Dis, 63(4), 548-554. doi: 10.1093/cid/ciw335.